Skip to main content

Advertisement

Log in

MicroRNA-630 is a prognostic marker for patients with colorectal cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

MicroRNAs are noncoding RNAs that regulate multiple cellular processes during cancer progression. Among various microRNAs, miR-630 has recently been identified to be implicated in many critical processes in human malignancies. We investigated the expression pattern and prognostic value of miR-630 in human colorectal cancer by utilizing cancer and adjacent normal specimens from 206 patients. Quantitative real-time PCR assay was used to detect the expression of miR-630, and appropriate statistical analysis was used to evaluate the association of miR-630 with overall survival. It was found that miR-630 expression was significantly increased in colorectal cancer specimens compared with that in adjacent normal specimens. It was also proved that miR-630 expression in colorectal cancer was associated with tumor invasion, lymph node metastasis, distant metastasis, and tumor-node-metastasis (TNM) stage. The Kaplan-Meier survival analysis proved that increased miR-630 expression was associated with poor overall survival of patients with colorectal cancer. Multivariate analysis proved that miR-630 was an independent prognostic marker after adjusted for known prognostic factors. These results confirmed the overexpression of miR-630 in human colorectal cancer and its association with tumor progression. It also suggested that miR-630 expression might serve as a prognostic biomarker for patients with colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.

    Article  PubMed  Google Scholar 

  3. Deng SX, An W, Gao J, Yin J, Cai QC, Yang M, et al. Factors influencing diagnosis of colorectal cancer: a hospital-based survey in china. J Dig Dis. 2012;13:517–24.

    Article  PubMed  Google Scholar 

  4. Chen HM, Weng YR, Jiang B, Sheng JQ, Zheng P, Yu CG, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in china between 1990 and 2009. J Dig Dis. 2011;12:371–8.

    Article  CAS  PubMed  Google Scholar 

  5. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.

    Article  PubMed  Google Scholar 

  6. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168–85.

    Article  PubMed  Google Scholar 

  7. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.

    Article  CAS  PubMed  Google Scholar 

  8. Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett. 2005;579:5911–22.

    Article  CAS  PubMed  Google Scholar 

  9. Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2008;18:79–88.

    Article  CAS  PubMed  Google Scholar 

  10. Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer—implications for pathogenesis and therapy. Curr Pharm Des. 2013;19:1211–26.

    CAS  PubMed  Google Scholar 

  11. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol. 2010;42:1262–72.

    Article  CAS  PubMed  Google Scholar 

  12. Gotte M. MicroRNAs in breast cancer pathogenesis. Minerva Ginecol. 2010;62:559–71.

    CAS  PubMed  Google Scholar 

  13. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.

    Article  CAS  PubMed  Google Scholar 

  14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  15. Dela Cruz F, Matushansky I. MicroRNAs in chromosomal translocation-associated solid tumors: Learning from sarcomas. Discov Med. 2011;12:307–17.

    PubMed  Google Scholar 

  16. An J, Zhu X, Wang H, Jin X. A dynamic interplay between alternative polyadenylation and microRNA regulation: IMPLICATIONS for cancer (review). Int J Oncol. 2013;43:995–1001.

    CAS  PubMed  Google Scholar 

  17. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59:671–81.

    Article  CAS  PubMed  Google Scholar 

  18. Iorio MV, Croce CM. Microrna dysregulation in cancer: DIAGNOSTICS, monitoring and therapeutics. A Comprehensive Review. EMBO Mol Med. 2012;4:143–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Okayama H, Schetter AJ, Harris CC. MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Dig Dis. 2012;30 Suppl 2:9–15.

    Article  PubMed  Google Scholar 

  20. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130:2077–87.

    Article  CAS  PubMed  Google Scholar 

  21. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012;12:505.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol WJG. 2009;15:2089–96.

    Article  CAS  PubMed  Google Scholar 

  23. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34:1069–75.

    CAS  PubMed  Google Scholar 

  25. Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. MicroRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012;33:220–5.

    Article  CAS  PubMed  Google Scholar 

  26. Liu L, Chen L, Xu Y, Li R, Du X. Microrna-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400:236–40.

    Article  CAS  PubMed  Google Scholar 

  27. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. Mir-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010;70:1793–803.

    Article  CAS  PubMed  Google Scholar 

  28. Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-deltanp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ. 2011;18:1220–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Huang Y, Guerrero-Preston R, Ratovitski EA. Phospho-deltanp63alpha-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle. 2012;11:1247–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One. 2013;8:e61015.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Wang XY, Wu MH, Liu F, Li Y, Li N, Li GY, et al. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol Cell Biochem. 2010;345:283–90.

    Article  CAS  PubMed  Google Scholar 

  32. Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1113–9.

    Article  CAS  PubMed  Google Scholar 

  33. Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, et al. Mir-630 targets IGF1R to regulate response to her-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014;13:71.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81201927, 81272204, and 31270812) and China Postdoctoral Science Foundation (grant number 2012M521862).

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dake Chu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chu, D., Zheng, J., Li, J. et al. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumor Biol. 35, 9787–9792 (2014). https://doi.org/10.1007/s13277-014-2223-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2223-3

Keywords

Navigation